COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 24, 2022
app pub date -
Feb 21, 2020
filing date -
Feb 21, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., EGFRvIII, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., EGFRvIII, in combination with a PD-1 inhibitor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully